nach oben

Arthritis Research & Therapy

Erschienen in:

01.08.2013 | Review

Natural killer cells in human autoimmune disorders

verfasst von: Leslie A Fogel, Wayne M Yokoyama, Anthony R French

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Natural killer (NK) cells are innate lymphocytes that play a critical role in early host defense against viruses. Through their cytolytic capacity and generation of cytokines and chemokines, NK cells modulate the activity of other components of the innate and adaptive immune systems and have been implicated in the initiation or maintenance of autoimmune responses. This review focuses on recent research elucidating a potential immunoregulatory role for NK cells in T-cell and B-cell-mediated autoimmune disorders in humans, with a particular focus on multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematous. A better understanding of the contributions of NK cells to the development of autoimmunity may lead to novel therapeutic targets in these diseases.

Progress in Autoimmune Diseases Research. [http://www.niaid.nih.gov/topics/autoimmune/documents/adccfinal.pdf]

The Cost Burden of Autoimmune Disease: The Latest Front in the War on Healthcare Spending. [http://www.aarda.org/pdf/cbad.pdf]

Yokoyam a WM, Kim S, French AR: The dynamic life of natural killer cells. Annu Rev Immunol. 2004, 22: 405-429. 10.1146/annurev.immunol.22.012703.104711.

Walzer T, Jaeger S, Chaix J, Vivier E: Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol. 2007, 19: 365-372. 10.1016/j.coi.2007.04.004.PubMed

Shi F-D, Ljunggren HG, La Cava A, Van Kaer L: Organ-specific features of natural killer cells. Nat Rev Immunol. 2011, 11: 658-671. 10.1038/nri3065.PubMedCentralPubMed

Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O: Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006, 12: 1065-1074. 10.1038/nm1452.PubMed

King A, Burrows T, Verma S, Hiby S, Loke YW: Human uterine lymphocytes. Hum Reprod Update. 1998, 4: 480-485. 10.1093/humupd/4.5.480.PubMed

Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA: Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001, 97: 3146-3151. 10.1182/blood.V97.10.3146.PubMed

Caligiuri MA: Human natural killer cells. Blood. 2008, 112: 461-469. 10.1182/blood-2007-09-077438.PubMedCentralPubMed

10.

Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA: CD56^bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003, 101: 3052-3057. 10.1182/blood-2002-09-2876.PubMed

11.

Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P: The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995, 181: 1133-1144. 10.1084/jem.181.3.1133.PubMed

12.

Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M: NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994, 180: 1235-1242. 10.1084/jem.180.4.1235.PubMed

13.

Braud VM, Allen DSJ, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ: HLA-E binds to natural-killer-cell receptors CD94/NKG2A, B and C. Nature. 1998, 391: 795-799. 10.1038/35869.PubMed

14.

Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998, 187: 813-818. 10.1084/jem.187.5.813.PubMedCentralPubMed

15.

Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, Geraghty DE: HLA-E is a major ligand for the NK inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA. 1998, 95: 5199-5204. 10.1073/pnas.95.9.5199.PubMedCentralPubMed

16.

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999, 285: 727-729. 10.1126/science.285.5428.727.PubMed

17.

Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A: Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001, 409: 1055-1060. 10.1038/35059110.PubMed

18.

Ljunggren HG, Karre K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990, 11: 237-244.PubMed

19.

Kärre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986, 319: 675-678. 10.1038/319675a0.PubMed

20.

Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005, 436: 1186-1190. 10.1038/nature03884.PubMedCentralPubMed

21.

Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O: Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol. 2008, 9: 1065-1073. 10.1038/ni.1642.PubMed

22.

Jonsson AH, Yokoyama WM: Natural killer cell tolerance licensing and other mechanisms. Adv Immunol. 2009, 101: 27-79.PubMed

23.

Elliott JM, Yokoyama WM: Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. 2011, 32: 364-372. 10.1016/j.it.2011.06.001.PubMedCentralPubMed

24.

Zimmer J, Donato L, Hanau D, Cazenave JP, Tongio MM, Moretta A, de la Salle H: Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 1998, 187: 117-122. 10.1084/jem.187.1.117.PubMedCentralPubMed

25.

Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E: Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006, 25: 331-342. 10.1016/j.immuni.2006.06.013.PubMed

26.

Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH: A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005, 105: 4416-4423. 10.1182/blood-2004-08-3156.PubMedCentralPubMed

27.

Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005, 436: 709-713. 10.1038/nature03847.PubMed

28.

Yokoyama WM, Kim S: Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev. 2006, 214: 143-154. 10.1111/j.1600-065X.2006.00458.x.PubMed

29.

Yokoyama WM, Kim S: How do natural killer cells find self to achieve tolerance?. Immunity. 2006, 24: 249-257. 10.1016/j.immuni.2006.03.006.PubMed

30.

Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM: HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA. 2008, 105: 3053-3058. 10.1073/pnas.0712229105.PubMedCentralPubMed

31.

Mailliard RB, Son Y-I, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P: Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003, 171: 2366-2373.PubMed

32.

Piccioli D, Sbrana S, Melandri E, Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002, 195: 335-341. 10.1084/jem.20010934.PubMedCentralPubMed

33.

Mocikat R, B raumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmuller G, Koszinowski U, Röcken M: Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003, 19: 561-569. 10.1016/S1074-7613(03)00264-4.PubMed

34.

Ferlazzo G, T sang ML, Moretta L, Melioli G, Steinman RM, Münz C: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002, 195: 343-351. 10.1084/jem.20011149.PubMedCentralPubMed

35.

Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, Lazzeri E, Lasagni L, Martini S, Rivera P, Capobianco A, Moretta L, Moretta A, Bottino C: Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killerdendritic cell interaction. Blood. 2006, 107: 2030-2036. 10.1182/blood-2005-07-2696.PubMed

36.

Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vély F, Pende D, Trowsdale J, Vivier E, Gordon S, Davis DM: Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood. 2007, 109: 3776-3785. 10.1182/blood-2006-10-052977.PubMed

37.

Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A: Antigenactivated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood. 2007, 110: 606-615. 10.1182/blood-2006-10-052720.PubMed

38.

Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW: Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol. 2006, 67: 170-182. 10.1016/j.humimm.2006.02.010.PubMed

39.

Zingoni A, Palmieri G, Morrone S, Carretero M, Lopez-Botel M, Piccoli M, Frati L, Santoni A: CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur J Immunol. 2000, 30: 644-651. 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H.PubMed

40.

De Maria A, Fogli M, Mazza S, Basso M, Picciotto A, Costa P, Congia S, Mingari MC, Moretta L: Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol. 2007, 37: 445-455. 10.1002/eji.200635989.PubMed

41.

Mehrotra PT, Donnelly RP, Wong S, Kanegane H, Geremew A, Mostowski HS, Furuke K, Siegel JP, Bloom ET: Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol. 1998, 160: 2637-2644.PubMed

42.

Deniz G, Erten G, Kücüksezer UC, Kocacik D, Karagiannidis C, Aktas E, Akdis CA, Akdis M: Regulatory NK cells suppress antigen-specific T cell responses. J Immunol. 2008, 180: 850-857.PubMed

43.

Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004, 5: 1260-1265. 10.1038/ni1138.PubMed

44.

Morandi B, Bougra s G, Muller WA, Ferlazzo G, Munz C: NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol. 2006, 36: 2394-2400. 10.1002/eji.200636290.PubMed

45.

Grossman WJ, Verb sky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004, 21: 589-601. 10.1016/j.immuni.2004.09.002.PubMed

46.

Risma K, Jordan MB: Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012, 24: 9-15. 10.1097/MOP.0b013e32834ec9c1.PubMed

47.

Côte M, Ménager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, Al-Manjomi F, Al-Harbi M, Alangari A, Le Deist F, Gennery AR, Prince N, Cariou A, Nitschke P, Blank U, El-Ghazali G, Ménasché G, Latour S, Fischer A, de Saint Basile G: Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009, 119: 3765-3773. 10.1172/JCI40732.PubMedCentralPubMed

48.

Schleinitz N, Vély F, Harlé J-R, Vivier E: Natural killer cells in human autoimmune diseases. Immunology. 2010, 131: 451-458. 10.1111/j.1365-2567.2010.03360.x.PubMedCentralPubMed

49.

Grunebaum E, Malatzky-Goshen E, Shoenfeld Y: Natural killer cells and autoimmunity. Immunol Res. 1989, 8: 292-304. 10.1007/BF02935514.PubMed

50.

Baxter AG, Smyth MJ: The role of NK cells in autoimmune disease. Autoimmunity. 2002, 35: 1-14. 10.1080/08916930290005864.PubMed

51.

Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG: The natural killer cell-friend or foe in autoimmune disease?. Scand J Immunol. 2002, 55: 432-441. 10.1046/j.1365-3083.2002.01084.x.PubMed

52.

French AR, Yokoyama WM: N atural killer cells and autoimmunity. Arthritis Res Ther. 2004, 6: 8-14.PubMedCentralPubMed

53.

Flodström-Tullberg M, Bryceson YT, Shi F-D, Höglun d P, Ljunggren H-G: Natural killer cells in human autoimmunity. Curr Opin Immunol. 2009, 21: 634-640. 10.1016/j.coi.2009.09.012.PubMed

54.

Tian Z, Gershwin ME, Zhang C: Regulatory NK cells in autoimmune disease. J Autoimmun. 2012, 39: 206-215. 10.1016/j.jaut.2012.05.006.PubMed

55.

Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, Shin MH, Park JJ, Kim TJ, Lee SS, Yoo DH, Kang HS: Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 1753-1763. 10.1002/art.24556.PubMed

56.

Bossowski A, Urban M, Stasiak-Barmuta A: Analysis of circulating T gamma/ delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease. Pediatr Res. 2003, 54: 425-429. 10.1203/01.PDR.0000076663.94850.44.PubMed

57.

Ciampolillo A, Guastamacchia E, Amati L, Magrone T, Munno I, Jirillo E, Triggiani V, Fallacara R, Tafaro E: Modifications of the immune responsiveness in patients with autoimmune thyroiditis: evidence for a systemic immune alteration. Curr Pharm Des. 2003, 9: 1946-1950. 10.2174/1381612033454270.PubMed

58.

Cameron AL, Kirby B, Griffiths CEM: Circulating natu ral killer cells in psoriasis. Br J Dermatol. 2003, 149: 160-164. 10.1046/j.1365-2133.2003.05319.x.PubMed

59.

O'Gorman MR, Smith R, Garrison A, Shamiyeh E, Pachman L: Lymphocyte subsets in peripheral blood from newly diagnosed, untreated patients with juvenile dermatomyositis (JDM) are associated with disease activity scores (DAS). Arthritis Rheum. 2002, 46: S490-

60.

Wouters CH, Ceuppens JL, Stevens EA: Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002, 20: 239-248.PubMed

61.

Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989, 320: 1731-1735. 10.1056/NEJM198906293202605.PubMed

62.

Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T: Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol. 1996, 103: 408-413.PubMedCentralPubMed

63.

Orange JS: Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 2002, 4: 1545-1558. 10.1016/S1286-4579(02)00038-2.PubMed

64.

Dotta F, Censini S, van Halteren AGS, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Muda AO, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P: Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA. 2007, 104: 5115-5120. 10.1073/pnas.0700442104.PubMedCentralPubMed

65.

Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R: Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008, 128: 1196-1206. 10.1038/sj.jid.5701183.PubMed

66.

Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR, Juvenile Dermatomyositis Research Group (UK and Ireland): MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004, 31: 605-609.PubMed

67.

Pachman L, O'Gorman MR, Lawton T, Liotta M, Pope RM, Greene M, Wu TT: Studies of muscle biopsies from DQA*501+ untreated children with juvenile dermatomyositis very early in their disease course: evidence of a TCRb8 motif and increase CD56+ NK cells. Arthritis Rheum. 1998, 41 (Suppl 9): 203-

68.

Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A: CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2006, 36: 118-128. 10.1002/eji.200535243.PubMed

69.

Dalbeth N, Callan MFC: A subset of natural killer cell s is greatly expanded within inflamed joints. Arthritis Rheum. 2002, 46: 1763-1772. 10.1002/art.10410.PubMed

70.

Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christm as SE, Moots RJ: Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56^bright,CD94^bright,CD158^negative phenotype. Rheumatology (Oxford). 2003, 42: 870-878. 10.1093/rheumatology/keg240.

71.

Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawai H, Komiyama A: A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol. 1996, 23: 171-177.PubMed

72.

Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, Mathis D: Altered natural killer cells in type 1 diabetic patients. Diabetes. 2007, 56: 177-185. 10.2337/db06-0493.PubMed

73.

Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan N G: Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009, 155: 173-181. 10.1111/j.1365-2249.2008.03860.x.PubMedCentralPubMed

74.

Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O: The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol. 2010, 11: 121-128. 10.1038/ni.1834.PubMed

75.

Poirot L, Benoist C, Mathis D: Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA. 2004, 101: 8102-8107. 10.1073/pnas.0402065101.PubMedCentralPubMed

76.

Brauner H, Elemans M, Lemos S, Broberger C, Holmberg D, Flodstrom-Tullberg M, Karre K, Hoglund P: Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol. 2010, 184: 2272-2280. 10.4049/jimmunol.0804358.PubMed

77.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW: A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol. 1998, 86: 123-133. 10.1016/S0165-5728(98)00014-9.PubMed

78.

Gonzalez-Amaro R, Alcocer-Varela J, Alarcón-Segovia D: Natural killer cell activity in dermatomyositis-polymyositis. J Rheumatol. 1987, 14: 307-310.PubMed

79.

Lima M, Almeida J, Montero AG, Teixeira Mdos A, Queiros ML, Santos AH, Balanzategui A, Estevinho A, Alguero Mdel C, Barcena P, Fonseca S, Amorim ML, Cabeda JM, Pinho L, Gonzalez M, San Miguel J, Justiça B, Orfão A: Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol. 2004, 165: 1117-1127. 10.1016/S0002-9440(10)63373-1.PubMedCentralPubMed

80.

Orange JS, Chehimi J, Ghavimi D, Campbell D, Sullivan KE: Decreased natural killer (NK) cell function in chronic NK cell lymphocytosis associated with decreased surface expression of CD11b. Clin Immunol. 2001, 99: 53-64. 10.1006/clim.2001.5002.PubMed

81.

French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM: Chronic lymphocytosis of functionally immature natural killer cells. J Allergy Clin Immunol. 2007, 120: 924-931. 10.1016/j.jaci.2007.05.022.PubMed

82.

Lamy T, Loughran TP: Clinical features of large granular lymphocyte leukemia. Semin Hematol. 2003, 40: 185-195. 10.1016/S0037-1963(03)00133-1.PubMed

83.

Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL: Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994, 84: 2721-2725.PubMed

84.

Rabbani GR, Phyliky RL, Tefferi A: A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999, 106: 960-966. 10.1046/j.1365-2141.1999.01624.x.PubMed

85.

Bashirova AA, Martin MP, McVicar DW, Carrington M: The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006, 7: 277-300. 10.1146/annurev.genom.7.080505.115726.PubMed

86.

Kulkarni S, Martin MP, Carrington M: The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008, 20: 343-352. 10.1016/j.smim.2008.06.003.PubMedCentralPubMed

87.

Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert J J, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O'Brien SJ, Carrington M: Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002, 31: 429-434.PubMed

88.

Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, Lifson JD, Allen TM, Carrington M, Altfeld M: Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007, 204: 3027-3036. 10.1084/jem.20070695.PubMedCentralPubMed

89.

Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, Goronzy JJ: Major histocompatibility complex class i-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001, 193: 1159-1168. 10.1084/jem.193.10.1159.PubMedCentralPubMed

90.

Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M: Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol. 2002, 169: 2818-2822.PubMed

91.

van der Slik AR, Koeleman BPC, Verduijn W, Bruining GJ, Roep BO, Giphart MJ: KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003, 52: 2639-2642. 10.2337/diabetes.52.10.2639.PubMed

92.

Takeno M, Shimoyama Y, Kashiwakura J-I, Nagafuchi H, Sakane T, Suzuki N: Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behçet's disease. Rheumatol Int. 2004, 24: 212-216.PubMed

93.

Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M: Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol. 2004, 173: 4273-4276.PubMed

94.

Chan AT, Kollnberger SD, Wedderburn LR, Bowness P: Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005, 52: 3586-3595. 10.1002/art.21395.PubMed

95.

Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA, Agliardi C, Gallotti J, Morra VB, Florio C, Clerici M, Lombardi ML: KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J Neuroimmunol. 2010, 229: 232-237. 10.1016/j.jneuroim.2010.08.004.PubMed

96.

Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD: KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens. 2007, 69 (Suppl 1): 106-108.PubMed

97.

Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, Witte T: Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 2004, 50: 1561-1565. 10.1002/art.20216.PubMed

98.

Morandi B, Bramanti P, Bonaccorsi I, Montalto E, Oliveri D, Pezzino G, Navarra M, Ferlazzo G: Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res. 2008, 57: 1-5. 10.1016/j.phrs.2007.11.003.PubMed

99.

Gandhi R, Laroni A, Weiner HL: Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2010, 221: 7-14. 10.1016/j.jneuroim.2009.10.015.PubMedCentralPubMed

100.

Jiang W, Chai NR, Maric D, Bielekova B: Unexpected role for granzyme K in CD56^bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol. 2011, 187: 781-790. 10.4049/jimmunol.1100789.PubMedCentralPubMed

101.

Morse RH, Séguin R, McCrea EL, Antel JP: NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol. 2001, 116: 107-115. 10.1016/S0165-5728(01)00289-2.PubMed

102.

Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, Cayrol R, Prat A, Hall JA, Arbour N: NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci. 2007, 27: 1220-1228. 10.1523/JNEUROSCI.4402-06.2007.PubMed

103.

Zhang BN, Yamamura T, Kondo T, Fujiwara M, Tabira T: Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med. 1997, 186: 1677-1687. 10.1084/jem.186.10.1677.PubMedCentralPubMed

104.

Matsumoto Y, Kohyama K, Aikawa Y, Shin T, Kawazoe Y, Suzuk i Y, Tanuma N: Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol. 1998, 28: 1681-1688. 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T.PubMed

105.

Xu W, Fazekas G, Hara H, Tabira T: Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005, 163: 24-30. 10.1016/j.jneuroim.2005.02.011.PubMed

106.

Huang D, Shi F-D, Jung S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM: The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006, 20: 896-905. 10.1096/fj.05-5465com.PubMed

107.

Winkler-Pickett R, Young HA, Cherry JM, Diehl J, Wine J, B ack T, Bere WE, Mason AT, Ortaldo JR: In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol. 2008, 180: 4495-4506.PubMed

108.

Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG: IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol. 2000, 165: 3099-3104.PubMed

109.

Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi F-D: Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol. 2005, 174: 2696-2701.PubMed

110.

Munschauer FE, Hartrich LA, Stewart CC, Jacobs L: Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol. 1995, 62: 177-181. 10.1016/0165-5728(95)00115-9.PubMed

111.

Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Has himoto S, Yamamura T: Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest. 2001, 107: R23-R29. 10.1172/JCI11819.PubMedCentralPubMed

112.

Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T: The regulatory role of natural killer cells in multiple sclerosis. Brain. 2004, 127 (Pt 9): 1917-1927.PubMed

113.

Hamann I, Dörr J, Glumm R, Chanvillard C, Janssen A, Millward JM, Paul F, Ransohoff RM, Infante-Duarte C: Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol. 2012, 254: 165-169.PubMed

114.

Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Ce rna M, Waldmann TA, McFarland H, Henkart PA, Martin R: Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006, 103: 5941-5946. 10.1073/pnas.0601335103.PubMedCentralPubMed

115.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohay on J, Waldmann TA, McFarland HF, Martin R: Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009, 66: 483-489. 10.1001/archneurol.2009.50.PubMedCentralPubMed

116.

Ahern DJ, Brennan FM: The role of natural killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?. Immunol Lett. 2011, 136: 115-121. 10.1016/j.imlet.2010.11.001.PubMed

117.

Conigliaro P, Scrivo R, Valesini G, Perricone R: Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev. 2011, 10: 577-581. 10.1016/j.autrev.2011.04.017.PubMed

118.

Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJ, Erkelens GW, Meinders AE, Kluin PM, Breedveld FC: Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum. 1994, 37: 1735-1743. 10.1002/art.1780371205.PubMed

119.

de Matos CT, Berg L, Michaëlsson J, Felländer-Tsai L, Kärre K, Söderström K: Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology. 2007, 122: 291-301. 10.1111/j.1365-2567.2007.02638.x.PubMedCentralPubMed

120.

Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, K lareskog L, Tarner IH, Engleman EG, Söderström K: Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood. 2007, 110: 2484-2493. 10.1182/blood-2007-02-076364.PubMedCentralPubMed

121.

Ren J, Feng Z, Lv Z, Chen X, Li J: Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α. J Rheumatol. 2011, 38: 2112-2118. 10.3899/jrheum.101377.PubMed

122.

Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA. 2003, 100: 9452-9457. 10.1073/pnas.1632807100.PubMedCentralPubMed

123.

Aramaki T, Ida H, Izumi Y, Fujikawa K, Huang M, Arima K, Tamai M, Kamachi M, Nakamura H, Kawakami A, Origuchi T, Matsuoka N, Eguchi K: A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol. 2009, 19: 245-252. 10.1007/s10165-009-0160-6.PubMed

124.

Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W: Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003, 42: 375-379. 10.1093/rheumatology/keg074.

125.

Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A: Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003, 142: 292-296. 10.1067/mpd.2003.110.PubMed

126.

Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA: Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005, 7: R30-R37. 10.1186/ar1453.PubMedCentralPubMed

127.

de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ: Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60: 2782-2793. 10.1002/art.24750.PubMed

128.

Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KMK, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W: Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2010, 49: 441-449. 10.1093/rheumatology/kep418.

129.

Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, Binstadt BA: Mutations of the hemophagocytic lymphohistiocytosisassociated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008, 58: 567-570. 10.1002/art.23199.PubMed

130.

Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA: Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008, 58: 2892-2896. 10.1002/art.23734.PubMedCentralPubMed

131.

Lo CKC, Lam QLK, Sun L, Wang S, Ko K-H, Xu H, Wu C-Y, Zheng B-J, Lu L: Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum. 2008, 58: 2700-2711. 10.1002/art.23760.PubMed

132.

Nilsson N, Bremell T, Tarkowski A, Carlsten H: Protective role of NK 1.1⁺ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol. 1999, 117: 63-69. 10.1046/j.1365-2249.1999.00922.x.PubMedCentralPubMed

133.

Wu H-J, Sawaya H, Binstadt B, Brickelmaier M, Blasius A, Gorelik L, Mahmood U, Weissleder R, Carulli J, Benoist C, Mathis D: Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J Exp Med. 2007, 204: 1911-1922. 10.1084/jem.20070285.PubMedCentralPubMed

134.

Leavenworth JW, Wang X, Wenander CS, Spee P, Cantor H: Mobilization of natural killer cells inhibits development of collagen-induced arthritis. Proc Natl Acad Sci USA. 2011, 108: 14584-14589. 10.1073/pnas.1112188108.PubMedCentralPubMed

135.

Söderström K, Stein E, Colmenero P, Purath U, Müller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG: Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci USA. 2010, 107: 13028-13033. 10.1073/pnas.1000546107.PubMedCentralPubMed

136.

Yuan D, Thet S, Zhou XJ, Wakeland EK, Dang T: The role of NK cells in the development of autoantibodies. Autoimmunity. 2011, 44: 641-651. 10.3109/08916934.2011.587852.PubMed

137.

Takeda K, Dennert G: The development of autoimmunity in C57BL/6 lprmice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med. 1993, 177: 155-164. 10.1084/jem.177.1.155.PubMed

138.

Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, Wei H: Involvement of CD2 26+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol. 2011, 186: 3421-3431. 10.4049/jimmunol.1000569.PubMedCentralPubMed

139.

Schleinitz N, Chiche L, Guia S, Bouvier G, Vernier J, Morice A, Houssaint E, Harlé J-R, Kaplanski G, Montero-Julian FA, Vély F: Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients. PLoS ONE. 2009, 4: e6264-10.1371/journal.pone.0006264.PubMedCentralPubMed

140.

Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debré P, Amoura Z, Vieillard V: Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum. 2011, 63: 1698-1706. 10.1002/art.30313.PubMed

141.

Puxeddu I, Bongiorni F, Chimenti D, Bombardieri S, Moretta A, Bottino C, Migliorini P: Cell surface expression of activating receptors and coreceptors on peripheral blood NK cells in systemic autoimmune diseases. Scand J Rheumatol. 2012, 41: 298-304. 10.3109/03009742.2011.648657.PubMed

142.

Erkeller-Yuksel FM, Lydyard PM, Isenberg DA: Lack of NK cells in lupus patients with renal involvement. Lupus. 1997, 6: 708-712. 10.1177/096120339700600905.PubMed

143.

Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, Favaroni M, Strom R: Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity?. Lupus. 2000, 9: 333-337. 10.1191/096120300678828460.PubMed

144.

Schepis D, Gunnarsson I, Eloranta M-L, Lampa J, Jacobson SH, Kärre K, Berg L: Increased proportion of CD56^bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology. 2009, 126: 140-146. 10.1111/j.1365-2567.2008.02887.x.PubMedCentralPubMed

145.

Green MRJ, Kennell ASM, Larche MJ, Seifert MH, Isenberg DA, Salaman MR: Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol. 2005, 141: 165-173. 10.1111/j.1365-2249.2005.02822.x.PubMedCentralPubMed

Titel: Natural killer cells in human autoimmune disorders
verfasst von: Leslie A Fogel
Wayne M Yokoyama
Anthony R French
Publikationsdatum: 01.08.2013
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 4/2013
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar4232

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Natural killer cells in human autoimmune disorders

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

What autoantibody tests should become widely available to help scleroderma diagnosis and management?

Update on differences between childhood-onset and adult-onset systemic lupus erythematosus

Genomic characterization of remission in juvenile idiopathic arthritis

Hyaluronic acid fragments enhance the inflammatory and catabolic response in human intervertebral disc cells through modulation of toll-like receptor 2 signalling pathways

Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin